Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
Surrozen, Inc. announced its Q2 2026 financial results and business progress, including a planned IND submission for its SZN-8141 drug candidate targeting diabetic macular edema (DME) by end of Q3 2026 and beginning its Phase 1b/2a clinical study, DUET, by year-end 2026. The company also reported a key US patent challenge was denied, strengthening …